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During cancer invasion and metastasis, tumour cells actively
traverse host cellular and extracellular matrix barriers (Mignatti
and Rifkin, 1993). Proteolytic enzymes of the plasminogen activa-
tion system released by the neoplastic cells and/or the surrounding
tumour stroma accomplish invasion into the surrounding normal
tissue by degradation of basement membranes and extracellular
matrix proteins (Liotta et al, 1982; Danø et al, 1985; Mignatti and
Rifkin, 1993). Central to this system is the conversion of the
abundant zymogen plasminogen into active plasmin, which is able
to degrade several extracellular proteins and to activate latent
prometalloproteases (Duffy, 1992; Mignatti and Rifkin, 1993;
Andreasen et al, 1997). The activation of plasminogen can be
catalysed by urokinase-type plasminogen activator (uPA) and
tissue-type plasminogen activator (tPA), the activities of both
enzymes being controlled by 2 plasminogen activator inhibitors,
PAI-1 and PAI-2 (Andreasen et al, 1990, 1997). Binding of uPA to
its specific cellular receptor, uPAR, is considered to be an impor-
tant step in the proteolytic cascade, since this receptor localizes the
proteolytic activities to the cell surface and strongly enhances
activation of surface-bound plasminogen (Danø et al, 1994). 
Human uPAR is a heavily glycosylated protein of approxi-
mately 60 kDa comprising three homologous domains (Behrendt
et al, 1995). The receptor is anchored in the plasma membrane 
by a carboxyl-terminally attached glycosyl-phosphatidylinositol
moiety which is responsible for the hydrophobicity of the protein
(Ploug et al, 1991). Primarily, uPA binds to the amino-terminal
domain of uPAR, while other domains appear to critically
contribute to strong ligand binding (Behrendt et al, 1996). It has
been shown that uPAR acts as a high-affinity receptor for the
matrix-like form of vitronectin also (Waltz and Chapman, 1994;
Wei et al, 1994; Kanse et al, 1996). This function of uPAR,
together with its ability to interact with the cytoskeleton-engaged
integrins (Wei et al, 1996), implicate uPAR in regulation of cell
adhesion and migration, in addition to mediation of cellular
signalling (Chapman, 1997). 
Many studies have shown that uPA and PAI-1 are prognostic
factors in several types of cancer, including breast cancer, high
tissue levels of both components being associated with reduced
disease-free and/or overall survival (reviewed by Duffy, 1996 and
Schmitt et al, 1997). Relatively few studies have reported on the
clinical relevance of uPAR in human cancer, though elevated
levels of uPAR have been shown to predict poor disease outcome
in breast cancer as well (Duggan et al, 1995; Grøndahl-Hansen et
al, 1995; Bouchet et al, 1999; Foekens et al, 2000). Recently, we
evaluated the clinical relevance of uPA, tPA and PAI-1 determined
by a newly developed ELISA in cytosolic extracts as well as in
corresponding detergent extracts of pellets obtained after ultracen-
trifugation when preparing the cytosolic fractions (De Witte et al,
1999a, b). In the present study, we measured the antigen levels of
uPAR in the same cytosols and pellet extracts, employing a previ-
ously established ELISA (Rønne et al, 1995). Using both sub-
cellular fractions enables us to analyse direct correlations between
all components of the urokinase system and to weigh them against
each other. The quantitative ELISA results obtained were
compared and the prognostic information provided by uPAR in
these specimens was examined. 
MATERIALS AND METHODS 
Patients and tumour characteristics 
In the present study, only those 878 patients with primary operable
breast cancer were included for whom uPAR antigen levels were
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tumour biopsies. Inclusion criteria for patients from whom tumour
samples were stored in the tumour bank of the Rotterdam Cancer
Institute (Dr Daniel den Hoed Kliniek) were: (i) primary diagnosis
of breast cancer between 1979 and 1989; (ii) no signs of distant
metastasis at diagnosis; (iii) no previous diagnosis of carcinoma,
with the exception of basal cell skin cancer and cervical cancer
stage Ia; (iv) no evidence of disease within one month after
primary surgery. In case of mastectomy after an initial lumpec-
tomy for residual disease, the mastectomy is considered (as part
of) primary treatment. The median number of lymph nodes
removed surgically was 11. Patients without primary surgery or
patients who received neo-adjuvant treatment before primary
surgery, were excluded. Median age of the patients at the time of
surgery was 56 years (range 25–89 years). Radiotherapy was given
to 82% of the patients: on the breast/thoracic wall to 608 patients
and/or on the axilla to 259 patients, and/or on one or more lymph
node areas other than the axilla to 295 patients. While 2 of the 439
node-negative patients received adjuvant chemotherapy, none of
them received adjuvant hormonal therapy. Of the 430 node-posi-
tive patients (for 9 patients, nodal status missing), adjuvant
chemotherapy (mainly CMF; cyclophosphamide, methotrexate, 5-
fluorouracil) was given to 154 patients, while 58 patients received
hormonal therapy, either alone (45 patients) or in combination
with chemotherapy (13 patients). All patients were routinely
examined every 3 to 6 months during the first 5 years of follow-up
and once a year thereafter. 
During follow-up, 363 patients (41%) showed relapse, and
counted as failures in the analysis for relapse-free survival. 51
patients (7%) died without evidence of disease and were censored
at last follow-up in the analysis for relapse-free survival. 221
patients (25%) died after a previous relapse. A total of 282 patients
(32%) were counted as failures in the analysis for overall survival.
The median follow-up period of patients alive was 100 months
(range 12–167 months). 
Tumour tissue extraction 
Tumour tissues were stored in liquid nitrogen and pulverized in the
frozen state with a microdismembrator as recommended by the
European Organization for Research and Treatment of Cancer
(EORTC Breast Cancer Co-operative Group, 1980) for processing
of breast tumour tissue for cytosolic determination of steroid
hormone receptors (ER and PgR). The resulting tissue powder was
homogenized (weight/volume: 1/6) in EORTC receptor buffer (10
mM K2HPO4, containing 1.5 mM di-potassium chloride EDTA, 3
mM sodium azide, 10 mM monothioglycerol and 10% (v/v) glyc-
erol, pH = 7.4). The homogenate was centrifuged for 30 min at
100 000 g and 4˚C to obtain the supernatant fraction (cytosol). The
100 000 g pellets were re-homogenized with an Ultraturrax tissue
homogenizer in 20 mM Tris/HCl (pH = 8.5) containing 125 mM
NaCl. Following the addition of Triton X-100 to a final concentra-
tion of 1% and subsequent incubation for 16–20 h at 4˚C, the
supernatant fractions obtained by centrifugation at 30 000 g at 4˚C
were designated as pellet extracts. 
Steroid hormone receptor assays 
ER and PgR levels were determined by ligand-binding assay 
or enzyme immunoassay in cytosols as described previously
(Foekens et al, 1989). The cut-off level used as to classify tumours
as ER and PgR positive or negative was 10 fmol mg–1 cytosolic
protein. 
uPAR ELISA 
The antigen levels of uPAR in cytosols and pellet extracts were
assessed with an ELISA as described by Rønne and colleagues
(1995), with some minor modifications. Briefly, microtitreplates
were coated overnight at 4˚C with rabbit anti-uPAR antibodies.
Bound ligand was detected by subsequent incubation with non-
biotinylated mouse monoclonal anti-uPAR antibodies (clone R2,
R3 and R5) followed by incubation with horse-radish peroxidase-
labelled goat anti-mouse antibodies (Sigma Chemical Co, St
Louis, MO) diluted 1:500. Recombinant soluble uPAR was used as
standard in the ELISA (Rønne et al, 1994). The uPAR ELISA
detects free uPAR and uPAR in complex with uPA (Rønne et al,
1994). 
ELISA reagents were all diluted in PBS with 1% BSA and 0.1%
(v/v) Tween-20. Incubations with standards, samples and controls,
diluted in PBS-BSA-Tween, were performed overnight at 4˚C. All
determinations were performed in duplicate. Triton X-100 did not
have any influence on the ELISA up to a concentration of 1%. The
reproducibility of assay performance was controlled by analysis of
an aliquot of a pooled breast tumour cytosol sample in each assay-
run and the between-assay variation was found to be below 10%.
The within-assay variation of samples measured in duplicate was
always below 5%. The detection limit of the assay was 24 pg ml–1. 
Protein determinations 
The Bradford method for protein analysis (Bradford, 1976) was
employed using the Bio-Rad reagent with human serum albumin
(KabiVitrum, Stockholm, Sweden) as a standard in order to ex-
press antigen levels per mg of total protein. Triton X-100 up to a
concentration of 1% did not interfere with the protein determina-
tion in pellet extracts. 
Statistical analysis 
The strength of the associations of uPAR antigen levels deter-
mined in cytosols and pellet extracts with age and steroid hormone
receptor status was tested with Spearman rank correlation (rs). The
associations of uPAR with other clinical variables were tested with
the non-parametric Wilcoxon Rank-Sum test or the Kruskal-Wallis
test, including a Wilcoxon-type test for trends across ordered
groups where appropriate. Relapse-free and overall survival prob-
abilities were calculated by the actuarial method of Kaplan and
Meier (Kaplan and Meier, 1958). Both uni- and multivariate
analyses were performed using the Cox proportional hazard
model, and the associated likelihood ratio test was used to test for
differences. The Log-rank test for trends was used to test ordered
variables. To evaluate the prognostic value of uPAR in addition to
classical prognostic factors, a basic model was introduced. The
prognostic significance of additional biochemical variables (uPA,
tPA, and PAI-1) was tested in a final model, in which the 
basic model and all of the biochemical variables were included.
All computations were done with the STATA statistical package,
release 6.0 (STATA Corp, College Station, TX). Two-sided 
P-values below 0.05 were considered to be statistically significant. 
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uPAR in cytosols and pellet extracts 
The antigen levels of uPAR were determined in cytosols and corre-
sponding pellet extracts derived from primary breast cancer
patients. The cytosolic levels of uPAR varied from 0.00 to 9.88 ng
mg–1 protein (median 0.99 ng mg–1 protein; mean ± SD 1.13 ± 0.85
ng mg protein–1). The levels of uPAR in the pellet extracts were
significantly higher (P < 0.001) than those measured in the
cytosols and ranged from 0.00 to 204.90 ng mg–1 protein (median
3.38 ng mg–1 protein; mean ± SD 4.95 ± 10.58 ng mg protein–1).
The levels of uPAR in cytosols and pellet extracts were weakly but
significantly correlated (rs = 0.20, P < 0.001) (Figure 1). 
Relation of uPAR to patient and tumour characteristics 
The levels of uPAR determined in cytosols and pellet extracts were
related to patient and tumour characteristics (Table 1). The uPAR
levels were not or only marginally, negatively related with pa-
tient’s age. The uPAR levels in cytosols or pellet extracts were not
related with menopausal status and grade of differentiation. In
contrast to the levels of uPAR in cytosols, those measured in the
pellet extracts were negatively associated with both tumour size
and nodal status. Overall, higher levels of uPAR were measured in
steroid hormone receptor-negative tumours. The Spearman corre-
lation coefficients found for the cytosols were weak, i.e. rs = – 0.22
for uPAR and ER, and rs = –0.12 for uPAR and PgR. For the pellet
extracts these correlation coefficients were weak as well, i.e. –0.13
and –0.07, respectively. In both the cytosols and the pellet extracts
uPAR levels were strongly positively correlated with those of 
uPA and PAI-1 in the respective sample, with Spearman correla-
tions ranging from +0.42 to +0.63. In the cytosols, uPAR levels
were weakly negatively correlated with those of tPA (rs = –0.12)
while in the pellet extracts the relationship between uPAR and tPA
was weakly positive (rs = +0.10). 
Relation of uPAR to survival 
In order to analyse the relationship between uPAR and patient’s
survival in univariate analysis, the antigen levels were divided
into 4 groups (Q1 to Q4) by their respective quartiles. Regarding
the cytosolic extracts, the best value for discriminating between
patients with short and long survival corresponded to the third
quartile of the uPAR antigen levels (Table 2). Since there were no
significant associations between the uPAR levels in pellet extracts
and the rate of relapse and death (Table 2), the median value of the
respective uPAR levels was arbitrarily chosen to divide patients
into a ‘low-risk’ and a ‘high-risk’ group. When using these values
as cut-off points in repeated univariate analyses, high levels of
uPAR in cytosols (i.e. in Q4) were found to be associated with a
significantly reduced RFS and OS (Figure 2A, C). In contrast, high
levels of uPAR determined in pellet extracts (i.e. above the
median) appeared not to be significantly related to RFS or OS
(Figure 2B, D). 
The combined prognostic value of the cytosolic levels of uPAR
and of uPA, the latter previously determined in the same samples
(De Witte et al, 1999a), with respect to RFS and OS is visualized
in Figure 3. Patients with high levels of uPAR (i.e. in Q4) in their
tumours, which, in addition, contain high levels of uPA (i.e. above
the median value) experienced a very poor prognosis, while
patients with both low uPAR and low uPA tumour levels encoun-
tered a favourable prognosis. No further discrimination between
high-risk and low-risk patients was obtained when combining the
categorized levels of uPAR and uPA in pellet extracts (results not
shown). 
Cox multivariate regression analysis was performed to compare
the prognostic significance of uPAR with that of the classical
prognostic parameters comprising the basic multivariate model.
As reported earlier (De Witte et al, 1999), in the basic model, age
menopausal status, lymph node status, ER status and adjuvant
therapy were all significantly associated with both RFS and OS.
However, tumour size and PgR status were only statistically
significant in predicting OS, not RFS (results not shown). When
added to the basic multivariate model, uPAR measured in cytosols
(Q4 versus Q1–Q3) contributed to the prognostic information in the
analysis for OS, but not in the analysis for RFS. Likewise, uPAR in
pellet extracts (above versus below the median value) added to the
basic multivariate model for OS, but not for RFS (Table 3). 
A final model was analysed which included the basic multi-
variate model, the antigen levels of uPAR (Q4 versus Q1–Q3), as
well as the levels of uPA, tPA and PAI-1 (above versus below the
median values) determined previously in either the cytosols or the
pellet extracts (De Witte et al, 1999a,b). In the multivariate
analysis with the cytosolic variables, cytosolic PAI-1 appeared as
the only independent variable in analysis for RFS, while both uPA
and PAI-1 were associated with reduced OS. In the multivariate
model with the biochemical variables determined in the pellet
extracts, PAI-1 as well as tPA were associated with a reduced
(PAI-1) or prolonged (tPA) RFS and OS (Table 3). 
DISCUSSION 
In the present study we analysed uPAR antigen levels in 878 breast
tumour cytosols and corresponding detergent extracts of high-speed
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Figure 1 Correlation of uPAR antigen levels determined in cytosols and
pellet extracts derived from primary breast cancer patients. The solid line
corresponds to the line of equality. Values below the assay sensitivity were
set at half the detection limit (0.05 ng ml–1) of the ELISA. The antigen levels
are expressed as ng mg–1 of total protein content measured in the cytosols
and pellet extracts pellets employing a slightly modified version of a previously
developed ELISA. This ELISA has also been used before to eval-
uate the clinical relevance of uPAR in primary breast tumour
(Grøndahl-Hansen et al, 1995; Foekens et al, 2000). In both
studies, uPAR antigen levels were measured in cytosols routinely
prepared for steroid hormone receptor determination, while
Grøndahl-Hansen et al (1995) also measured uPAR in corresponding
detergent-treated homogenates of the same breast tumour samples. 
The cytosolic levels of uPAR found in the present study were
highly comparable to the cytosolic levels reported by Grøndahl-
Hansen et al (1995) and Foekens et al (2000) (median: 0.87 versus
0.99 and 0.94 ng mg–1, respectively). Evidently, this finding is a
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Table 1 Relationships of uPAR antigen levels in 878 cytosols and pellet extracts with patient and tumour
characteristics 
Characteristics  Number of patients1 Percentage of tumours above the median value2
uPARcytosol
3 uPARpellet
3
All patients  878  50  50 
Age at surgery (y) 
≤40 122 52 55 
41–55 301  51  50 
56–70 290  50  51 
>70 165 44 45 
P value4 0.04 0.09 
Menopausal status 
Pre-menopausal 361  51  51 
Post-menopausal 517  48  50 
P value5 0.07 0.41 
Tumour size 
T1 (≤2 cm) 397  48  56 
T2 (>2–5 cm) 396  52  46 
T3/4 (>5 cm) 85 46  42 
P value6 0.51 <0.001 
Nodal status 
N0 439 51 54 
N1–3 211 46 49 
N>3 219 48 42 
P value6 0.99 0.003 
Grade 
Well/moderate 151  48  53 
Poor 503  49  51 
P value5 0.84 0.68 
ER positive7
No 207  64  60 
Yes 670 45 47 
P value4 <0.001 <0.001 
PgR positive7
No 248  57  57 
Yes 616 46 48 
P value4 0.001 0.03 
uPA8
Low 434/4349 30 27 
High 444/4359 69 72 
P value4 <0.001 <0.001 
PAI-18
Low 435/4399 34 32 
High 443/4349 64 68 
P value4 <0.001 <0.001 
tPA8
Low 434/4359 53 46 
High 437/4309 46 54 
P value4 <0.001 0.002 
1Due to missing values the numbers do not always add up to 878. 2The median values in ng mg protein–1 were 0.99
for uPARcytosol and 3.38 for uPARpellet. 3uPARcytosol and uPARpellet denotes uPAR levels determined in cytosol and pellet
extracts, respectively. 4P value for Spearman rank correlation. 5P value for Wilcoxon rank sum test (for grade: well and
moderate combined). 6P value for Kruskal-Wallis test, including a Wilcoxon-type test for trend. 7Cut-off point used for
ER and PgR: 10 fmol mg protein–1. 8Median values used to classify tumours as high and low in the cytosols and pellet
extracts were as published before; for uPA, 0.73 and 7.26 ng mg protein–1 (de Witte et al, 1999a), for PAI-1, 1.62 and
5.29 ng mg protein–1 (de Witte et al, 1999a), and for tPA, 2.40 and 13.01 ng mg protein–1 (de Witte et al, 1999b).
These biochemical assays are very sensitive and easily can be performed on as little as 25 mg of tissue. 9The number
of cytosols/pellet extracts. direct reflection of the application of the same ELISA to the same
type of tumour extracts. The presence of uPAR in the cytosolic
samples prepared with a detergent-free, neutral extraction buffer,
most probably represents a water-soluble form of native uPAR
which has lost its glycolipid membrane anchor. As has been
suggested earlier, soluble isoforms of membrane proteins like
uPAR may be generated by alternative RNA splicing or by
cleavage of a region between the membrane anchor and the mature
integral membrane protein by limited proteolysis (Ploug et al,
1992). Alternatively spliced mRNA variants have been identified
and characterized in both human and mouse cell lines and tissues
(Kristensen et al, 1991; Pyke et al, 1993). However, although the
uPAR in cytosols and pellet extracts derived from breast tumours 89
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Table 2 Cox univariate analyses of relapse-free and overall survival in 878 primary breast cancer patients as a function
of uPAR levels in cytosols and pellet extracts 
Factor  Relapse-free survival  Overall survival 
P value RHR1 (95% CI)  P value RHR1 (95% CI) 
uPAR cytosols
Q2 vs. Q1 0.68  1.11 (0.82–1.50)  0.85  1.03 (0.73–1.46) 
Q3 vs. Q1 0.69  1.06 (0.79–1.44)  0.54  1.11 (0.79–1.57) 
Q4 vs. Q1 0.050  1.34 (1.00–1.79)  0.033  1.43 (1.03–1.98) 
uPAR pellet extracts
Q2 vs. Q1 0.62  0.93 (0.70–1.24)  0.26  0.82 (0.58–1.16) 
Q3 vs. Q1 0.73  0.95 (0.71–1.27)  0.45  1.13 (0.82–1.56) 
Q4 vs. Q1 0.75  1.05 (0.79–1.40)  0.45  1.13 (0.82–1.57) 
1Relative hazard rate (RHR) with 95% confidence interval (CI). uPAR antigen levels in ng mg–1 protein, classified as
quarters (Q1–Q4): quartiles 0.69, 0.99 and 1.41 for cytosols and 2.26, 3.38 and 4.82 for pellet extracts. 
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Figure 2 Actuarial relapse-free and overall survival curves for all 878 breast cancer patients stratified by the levels of uPAR determined in cytosols (A and C)
and pellet extracts (B and D). Patients were divided into groups with uPAR levels below (‘uPAR low’) and above (‘uPAR high’) the third quartile (cytosols; cut-off
point 1.41 ng mg–1) or median value (pellet extracts; cut-off point 3.38 ng mg–1) as indicated in the legend to Table 2. Shown are the P values from the Log-rank
test for trend. RHR (95% CI), relative hazard rate (95% confidence interval) calculated by Cox regression analysis. Between parentheses the number of
failures/total number of patients in each group deduced protein molecules contain a uPA binding domain and lack
the glycolipid anchor attachment sites, expression of the corre-
sponding native proteins has not been demonstrated under natural
conditions. Therefore, a more plausible explanation for its pres-
ence in cytosols may be related to the pericellular proteolytic
activities mediated by uPAR during cancer invasion and metas-
tasis. Under these conditions, uPAR is likely to be exposed to a
proteolytic micro-environment in vivo where it may be solubilized
by phospholipases or proteases, like plasmin, and even may enter
the bloodstream, as has been implied by several authors (Ploug 
et al, 1992; Grøndahl-Hansen et al, 1995; Pappot et al, 1997;
Stephens et al, 1997). Indeed, recent publications have shown that
by measuring the soluble form of uPAR in peripheral blood impor-
tant prognostic information in patients with colon (Stephens et al,
1999) or ovarian cancer (Sier et al, 1998) can be obtained. We are
currently studying the prognostic role of soluble uPAR in blood
samples obtained from patient undergoing surgery for primary
breast cancer. 
The detergent-treated homogenates of breast tumour tissue used
by Grøndahl-Hansen and colleagues (1995) need to be distinguished
from the pellet extracts in this investigation. While the detergent-
treated homogenates most likely contain the lipophilic native as
well as the soluble form of uPAR, the pellet extracts should
contain exclusively the former variant of uPAR. Nevertheless, the
levels of uPAR determined in the pellet extracts were substantially
higher than those in the detergent-treated homogenates (median:
3.38 versus 1.66 ng mg–1 protein, mean 4.95 versus 1.91 ng mg–1
protein). Since different procedures were employed to prepare the
detergent-treated homogenates and the pellet extracts, a direct
comparison of the uPAR antigen levels measured is quite difficult.
However, the apparent discrepancy may be explained, in part, by
the higher total protein content in the detergent extracts (3.14 mg
ml–1) derived from the tumour homogenates as compared to the
pellet extracts (1.92 mg ml–1) in the present study, causing rela-
tively lower uPAR antigen levels in the former type of samples. 
In this study, the prognostic value of uPAR in primary breast
carcinomas as documented in earlier investigations by Duggan et
al (1995). Grøndahl-Hansen et al (1995), Bouchet et al (1999) 
and Foekens et al (2000) could be confirmed, high levels of uPAR
being associated with poor disease outcome. In univariate regres-
sion analysis, using the third quartile of the cytosolic uPAR levels
as a cut-off point, cytosolic uPAR was shown to predict a signifi-
cantly reduced RFS and especially OS in patients with elevated
levels of uPAR (Figure 2). In contrast, the uPAR levels in the pellet
extracts were not significantly related to patient’s survival (Figure 2).
In multivariate analysis, after correction for the classical prog-
nostic factors, high levels of uPAR determined in both cytosols
(i.e. in Q4) and pellet extracts (i.e. above the median value)
appeared as significant predictors of poor OS, but not RFS (Table
3). These findings are in agreement with the results obtained in the
study by Grøndahl-Hansen et al (1995) referred to above. In this
latter investigation, uPAR in cytosols and detergent-treated
homogenates appeared to be predictive of a shorter OS only, the
cytosolic samples providing the most pronounced prognostic
information. 
Amongst others, we have previously demonstrated that uPA,
PAI-1 and tPA determined either in cytosols or pellet extracts
derived from the same series of patients included in the present
study can be considered as independent prognostic markers (i.e.
independent of classical prognostic factors) in breast cancer (De
Witte et al, 1999a,b). When these biochemical variables in addi-
tion to uPAR, were included together with the classical prognostic
variables in multivariate models, PAI-1 in cytosols and pellet
extracts appeared to be the strongest biological prognostic para-
meter for RFS and OS (Table 3). This finding is in general agree-
ment with various other studies on the clinical relevance of
components of the plasminogen activation system. Although
different combinations of potential prognostic variables have been
included in the multivariate analyses performed in those studies,
the strong prognostic impact of PAI-1 antigen in breast cancer has
been consistently reported (see review by Schmitt et al, 1997;
Look and Foekens, 1999). 
The association of elevated tumour levels of uPAR with poor
prognosis is in good agreement with the proposed role of this
molecule in cancer invasion and metastasis. Indeed, uPA-mediated
degradation of extracellular matrix proteins is strongly enhanced
upon binding of uPA to uPAR (Ellis et al, 1991). In the present
study, the significance of the interaction of uPA with uPAR is
expressed by the observed powerful negative effect on disease
outcome when the cytosolic levels of both parameters were
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Figure 3 Actuarial relapse-free (A) and overall survival curves (B) for
patients stratified by the combined levels of uPAR and uPA determined in
cytosolic extracts of tumour tissue. Patients were divided into groups with
levels below (‘low’) or above (‘high’) the third quartile (uPAR levels in Q4) or
median value (uPA) of the respective antigen levels. RHR (95% CI), relative
hazard rate (95% confidence interval) calculated by Cox univariate
regression analysis. Between parentheses the number of failures/total
number of patients in each group combined (Figure 3). The uPAR ELISA employed in the present
study measures both the free, uncomplexed (soluble) form of
uPAR as well as (soluble) uPAR in complex with uPA, without
having the ability to distinguish between them (Rønne et al, 1995).
Considering the importance of the interplay between uPA and
uPAR with respect to the invasiveness of malignant cells, the
tumour levels of complexes between uPA and uPAR might repre-
sent an even stronger prognostic parameter than the levels of the
separate components. Therefore, the development of an ELISA for
the selective detection and quantitation of uPA:uPAR complexes in
tumour tissue extracts (De Witte et al, 1997) might be considered
highly relevant to the analysis of the potential prognostic impact of
uPA:uPAR complexes in breast cancer. 
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